

Call Title: HEALTH-2009-Single-Stage

Call identifier: FP7-HEALTH-2009-single-stage

Proposal submission and evaluation: Single-stage procedure

Date of publication: 3 September 2008

Deadline: 3 December 2008 at 17.00.00 (Brussels local time)

Indicative budget: EUR 476 million from the 2009 budget¹

The budget for this call is indicative. The final budget awarded to this call, following the evaluation of proposals, may vary:

- by up to 10% of the total value of the call; and
- the repartition of sub-budgets awarded within this call, following the evaluation of proposals, may vary by up to 10% of the total value of the call.

ACTIVITY/AREA		Indicative budget (EUR million)
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH		
1.2 DETECTION, DIAGNOSIS AND MONITORING		120
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES		
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS		
2. TRANSLATING RESEARCH FOR HUMAN HEALTH		
2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING	2.2.1. Brain and brain-related diseases	41
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH		75
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES		95
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS		
3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES		64
3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS		
3.3. ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION		
4. OTHER ACTIONS ACROSS THE HEALTH THEME	4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	3
	4.2. RESPONDING TO EU POLICY NEEDS	33
	4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)	
	4.3.1. Neglected infectious diseases	27
	4.3.2. International Public Health and Health Systems	12

¹ Under the condition that the preliminary draft budget for 2009 is adopted without modifications by the budgetary authority.

	4.3.3. Coordinated topics with Russia	6
--	---------------------------------------	---

Table 2: Topics called:

Activity/Area	Topics called	Funding Schemes
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH		
1.2 DETECTION, DIAGNOSIS AND MONITORING		
1.2	HEALTH-2009-1.2-1: Development of tools for sensitive and specific in vitro detection of proteins and their interactions for diagnostic, prognostics and monitoring purposes.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
1.2	HEALTH-2009-1.2-2: Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
1.2	HEALTH-2009-1.2-3: Novel MR-compatible PET detectors for simultaneous PET/MRI imaging.	<i>Collaborative Project (Large-scale integrating project)</i>
1.2	HEALTH-2009-1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
1.2	HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases	<i>Collaborative Project (Small or medium-scale focused research project)</i>
1.2	HEALTH-2009-1.2-6: Evaluation of the potential health impact of diagnostic imaging agents doses.	<i>Coordination and Support Action (Supporting Action)</i>
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES		
1.3	HEALTH-2009-1.3-1: New initiatives towards the implementation of the Replace, Reduce and Refine strategy.	<i>Coordination and Support Action (Coordinating or Supporting Action)</i>
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS		
1.4	HEALTH-2009-1.4-1: Cell therapy for tissue and organs.	<i>Collaborative Project (Large-scale integrating project)</i>
1.4	HEALTH-2009-1.4-2: Regeneration of tissue using bio-compatible materials and cells.	<i>Collaborative Project (Large-scale integrating project)</i>
1.4	HEALTH-2009-1.4-3: Activation of endogenous cells as an approach to regenerative medicine.	<i>Collaborative Project (Large-scale integrating project)</i>
2. TRANSLATING RESEARCH FOR HUMAN HEALTH		
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING		
2.2.1. Brain and brain-related diseases		
2.2.1.	HEALTH-2009-2.2.1-1: Synaptopathies: genesis, mechanisms and therapy.	<i>Collaborative Project (Large-scale integrating project)</i>
2.2.1.	HEALTH-2009-2.2.1-2: Identifying genetic and environmental interactions in schizophrenia.	<i>Collaborative Project (Large-scale integrating project)</i>
2.2.1.	HEALTH-2009-2.2.1-3: Optimising current therapeutic approaches to schizophrenia.	<i>Collaborative Project (Large-scale integrating project)</i>
2.2.1.	HEALTH-2009-2.2.1-4: Understanding the blood brain	<i>Collaborative Project (Small</i>

	barrier (BBB) to improve drug delivery to the brain.	<i>or medium-scale focused research project)</i>
2.2.1.	HEALTH-2009-2.2.1-5: Psycho-social factors of brain disorders.	<i>Coordination and Support Action (Coordinating Action)</i>
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH		
2.3.1. Anti-microbial drug resistance including fungal pathogens		
2.3.1	HEALTH-2009-2.3.1-1: Global collaborative research on the prevention of antibiotic resistance	<i>Collaborative Project (Large-scale integrating project)</i>
2.3.1	HEALTH-2009-2.3.1-2: Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.3.1.	HEALTH-2009-2.3.1-3: Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.3.2. HIV/AIDS, malaria and tuberculosis		
2.3.2.	HEALTH-2009-2.3.2-1: Integration of European efforts in research on malaria.	<i>Network of Excellence</i>
2.3.2.	HEALTH-2009-2.3.2-2: Identification and pre-clinical testing of new vaccine candidates for tuberculosis.	<i>Collaborative Project (Large-scale integrating project)</i>
2.3.2.	HEALTH-2009-2.3.2-3: Discovery and/or development of new and promising anti-HIV microbicides.	<i>Collaborative Project (Large-scale integrating project)</i>
2.3.2.	HEALTH-2009-2.3.2-4: Mucosal and topical vaccines for poverty-related diseases (HIV/AIDS, malaria and/or TB).	<i>Collaborative Project (Large-scale integrating project)</i>
2.3.2.	HEALTH-2009-2.3.2-5: Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.3.3. Potentially new and re-emerging epidemics		
2.3.3.	HEALTH-2009-2.3.3-1: Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES		
2.4.2. Cardiovascular diseases		
2.4.2.	HEALTH-2009-2.4.2-1: Improved or new therapeutic approaches for the treatment of heart failure.	<i>Collaborative Project (Large-scale integrating project)</i>
2.4.2.	HEALTH-2009-2.4.2-2: Cardiac arrhythmias: from genes to improved management of patients.	<i>Collaborative Project (Large-scale integrating project)</i>
2.4.2.	HEALTH-2009-2.4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.3. Diabetes and obesity		
2.4.3.	HEALTH-2009-2.4.3-1: Novel therapeutical approach to pregnancy-induced diabetes.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.3.	HEALTH-2009-2.4.3-2: Novel immunotherapies for type 1	<i>Collaborative Project (Large-</i>

	diabetes.	<i>scale integrating project</i>
2.4.3.	HEALTH-2009-2.4.3-3: Molecular pathways in food intake at CNS-liver-gut regulation level.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.4. Rare diseases		
2.4.4.	HEALTH-2009-2.4.4-1: Rare neurological diseases.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.4.	HEALTH-2009-2.4.4-2: Preclinical development of substances with a clear potential as orphan drugs.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.5. Other chronic diseases		
2.4.5.	HEALTH-2009-2.4.5-1: Prevention and treatment of non-alcoholic fatty liver disease (NAFLD).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
2.4.5.	HEALTH-2009-2.4.5-2: Cellular and molecular mechanisms of development of chronic kidney disease (CKD).	<i>Collaborative Project (Large-scale integrating project)</i>
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS		
3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES		
3.1.	HEALTH-2009-3.1-1: Patient Safety: Effective implementation of prevention strategies for healthcare associated infections.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.1.	HEALTH-2009-3.1-2: Improve quality and safety of hospital care.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.1.	HEALTH-2009-3.1-3: Complementary and Alternative Medicine.	<i>Coordination and Support Action (Coordinating Action)</i>
3.1.	HEALTH-2009-3.1-4: Improved treatment of chronic diseases in developing countries.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS		
3.2.	HEALTH-2009-3.2-1: Organisation of dementia care.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.2.	HEALTH-2009-3.2-2: Healthcare outcomes and cost-benefits.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.2.	HEALTH-2009-3.2-3: Primary care quality linkage to costs.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.2.	HEALTH-2009-3.2-4: Impact of cross border collaboration on health services.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.2.	HEALTH-2009-3.2-5: Research access to comparable	<i>Coordination and Support</i>

	healthcare data.	<i>Action (Coordinating Action)</i>
3.2.	HEALTH-2009-3.2-6: Scoping study to address the methodological challenges of quantifying the socio-economic burden of brain diseases in the enlarged European Union compared to other major diseases.	<i>Coordination and Support Action (Supporting Action)</i>
3.3. ENHANCED HEALTH PROMOTION AND DISEASE PREVENTION		
3.3.	HEALTH-2009-3.3-1: Child and adolescent mental health.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.3.	HEALTH-2009-3.3-2: Environmental prevention of substance abuse by adolescents.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
3.3.	HEALTH-2009-3.3-3: Ageing cohorts.	<i>Collaborative Project (Large-scale integrating project)</i>
3.3.	HEALTH-2009-3.3-4: Birth/Mother - Child Cohorts co-ordination	<i>Coordination and Support Action (Coordinating Action)</i>
3.3.	HEALTH-2009-3.3-5: European child health research platform	<i>Coordination and Support Action (Coordinating Action)</i>
4. OTHER ACTIONS ACROSS THE HEALTH THEME		
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME		
4.1.	HEALTH-2009-4.1-1: Monitoring tool and technology transfer analysis for health grants during FP7.	<i>Coordination and Support Action (Supporting Action)</i>
4.1.	HEALTH-2009-4.1-2: Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers.	<i>Coordination and Support Action (Coordinating or Supporting Action)</i>
4.1.	HEALTH-2009-4.1-3: Targeting publication bias.	<i>Coordination and Support Action (Supporting Action)</i>
4.2. RESPONDING TO EU POLICY NEEDS		
4.2.	HEALTH-2009-4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.2.	HEALTH-2009-4.2-2: Study of the Arrhythmogenic potential of different classes of medicines.	<i>Collaborative project (Small or medium-scale focused research project).</i>
4.2.	HEALTH-2009-4.2-3: Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.2.	HEALTH-2009-4.2-4: Coordinating action on organ procurement and transplantation with a focus on new EU Member States.	<i>Coordination and Support action (Coordinating action)</i>
4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)		
4.3.1. Neglected infectious diseases.		
4.3.1.	HEALTH-2009-4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections (SICA).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.3.1.	HEALTH-2009-4.3.1-2: Identification and development of	<i>Collaborative Project (Small</i>

	vaccine candidates for neglected bacterial infections (SICA).	<i>or medium-scale focused research project)</i>
4.3.1.	HEALTH-2009-4.3.1-3: Human immune responses to co-infections of poverty-Related (HIV, malaria, TB) and neglected infectious diseases (SICA).	<i>Collaborative Project (Large-scale integrating project)</i>
4.3.2. International Public Health and Health Systems		
4.3.2.	HEALTH-2009-4.3.2-1: Strategies and interventions for improving reproductive health (SICA).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.3.2.	HEALTH-2009-4.3.2-2: Access to medicines (SICA).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.3.2.	HEALTH-2009-4.3.2-3: Integration of Disease Surveillance and Health Systems Response (SICA).	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.3.3. Coordinated topics with Russia		
4.3.3.	HEALTH-2009-4.3.3-1 (SICA): Comparative population genetic studies on multifactorial diseases.	<i>Collaborative Project (Small or medium-scale focused research project)</i>
4.3.3.	HEALTH-2009-4.3.3-2: Mechanisms of diabetic and weight-related co-morbidity in heart failure (SICA).	<i>Collaborative Project (Small or medium-scale focused research project)</i>

Eligibility conditions:

The general eligibility criteria are set out in Annex 2 of the work programme. In addition, specific criteria apply to this call as set out below.

Eligibility criteria for each proposal are checked by Commission staff before the evaluation begins. Proposals which do not fulfil these criteria will not be included in the evaluation. For this call a proposal will only be considered eligible if it meets all of the following conditions:

- It is received by the Commission via the electronic proposal submission system respecting the deadline (date and time) as set out above.
- It involves at least the minimum number of participants as set out in the table below
- It is complete (i.e. both the requested administrative forms and the proposal description are present)
- The content of the proposal relates to the topic(s) and funding scheme(s), including any special conditions set out in the relevant parts of the work programme

It is important to note that the following ceilings for maximum EU contribution will be applied as an additional eligibility criterion and that proposals which do not respect these limits will be considered as ineligible:

- Large-scale integrating projects: the requested EC contribution shall be over EUR 6 million and not exceed EUR 12 million.
- Small or medium-scale focused research projects: the requested EC contribution shall not exceed EUR 3 million unless otherwise indicated in table 4.

- Coordination Actions: the requested EC contribution shall not exceed EUR 1.5 million unless otherwise indicated in table 4.
- Support Actions: the requested EC contribution shall not exceed EUR 0.5 million unless otherwise indicated in table 4.

The minimum number and type of participating legal entities for all funding schemes is set out in the FP7 Rules for Participation and summarised in the following table. There may be exceptions to the minimum number and participant type, which are specified in table 4.

Table 3: Eligibility conditions for each funding scheme

Funding scheme	Minimum conditions
Collaborative Project	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Networks of Excellence	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Collaborative project for specific cooperation Action (SICA) dedicated to international cooperation partner countries	At least 4 independent legal entities. Of these, 2 must be established in different MS or AC. The other 2 must be established in different international cooperation partner countries (ICPC).
Coordination and Support Action (coordinating action)	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Coordination and Support Action (supporting action)	At least 1 independent legal entity.

For some topics, additional eligibility criteria apply, over and above the criteria stated above (see table 4):

Table 4: Particular requirements for specific topics

Area	Topics	Particular requirements
1.2	HEALTH-2009-1.2-1: Development of tools for sensitive and specific in vitro detection of proteins and their interactions for diagnostic, prognostics and monitoring purposes.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
1.2	HEALTH-2009-1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy.	The requested European Community contribution in each project shall not exceed EUR 6 000 000. Only up to one project can be selected.
1.2	HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
1.2	HEALTH-2009-1.2-6: Evaluation of the potential health impact of diagnostic imaging agents doses.	Maximum of one project to be selected for each of the two areas specified in

		the topic description.
1.3	HEALTH-2009-1.3-1: New initiatives towards the implementation of the Replace, Reduce and Refine strategy.	The requested European Community contribution in each project shall not exceed EUR 1 000 000.
1.4	HEALTH-2009-1.4-1: Cell therapy for tissue and organs.	One or more projects can be selected.
1.4	HEALTH-2009-1.4-2: Regeneration of tissue using bio-compatible materials and cells.	One or more projects can be selected.
1.4	HEALTH-2009-1.4-3: Activation of endogenous cells as an approach to regenerative medicine.	One or more projects can be selected.
2.3.1	HEALTH-2009-2.3.1-2: Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
2.3.1.	HEALTH-2009-2.3.1-3: Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
2.3.2.	HEALTH-2009-2.3.2-5: Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB).	Only up to one project can be selected.
2.3.3.	HEALTH-2009-2.3.3-1: Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission.	Only up to one project can be selected.
2.4.3.	HEALTH-2009-2.4.3-1: Novel therapeutical approach to pregnancy-induced diabetes.	Only up to one project can be selected.
2.4.3.	HEALTH-2009-2.4.3-3: Molecular pathways in food intake at CNS-liver-gut regulation level.	Only up to one project can be selected.
2.4.4	HEALTH-2009-2.4.4-1: Rare neurological diseases.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
2.4.5.	HEALTH-2009-2.4.5-1: Prevention and treatment of non-alcoholic fatty liver disease (NAFLD).	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
3.2.	HEALTH-2009-3.2-4: Impact of cross border collaboration on health services.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
4.1.	HEALTH-2009-4.1-1: Monitoring tool and technology transfer analysis for health grants during FP7.	The requested European Community contribution in each project shall not exceed EUR 1 000 000.
4.1.	HEALTH-2009-4.1-2: Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers.	The requested European Community contribution in each project shall not exceed EUR 1 000 000. One or more projects can be selected.
4.2.	HEALTH-2009-4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations.	The requested European Community contribution in each project shall not exceed EUR 6 000 000.
4.2.	HEALTH-2009-4.2-2: Study of the Arrhythmogenic potential of different classes of medicines.	The requested European Community contribution in each project shall not exceed EUR 3 000 000.
4.2.	HEALTH-2009-4.2-3: Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease	Only up to one project can be selected.

	modelling and health economics.	
4.3.1.	HEALTH-2009-4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections (SICA).	The requested European Community contribution in each project shall not exceed EUR 6 000 000. SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ICPC Countries.
4.3.1.	HEALTH-2009-4.3.1-2: Identification and development of vaccine candidates for neglected bacterial infections (SICA).	The requested European Community contribution in each project shall not exceed EUR 6 000 000. SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ICPC Countries.
4.3.1.	HEALTH-2009-4.3.1-3: Human immune responses to co-infections of poverty-related (HIV, malaria, TB) and neglected infectious diseases (SICA).	SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ACP Countries.
4.3.2.	HEALTH-2009-4.3.2-1: Strategies and interventions for improving reproductive health (SICA).	SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ICPC Countries.
4.3.2.	HEALTH-2009-4.3.2-2: Access to medicines (SICA).	SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ICPC Countries.
4.3.2.	HEALTH-2009-4.3.2-3: Integration of Disease Surveillance and Health Systems Response (SICA).	SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from ACP Countries or Asian Countries.
4.3.3.	HEALTH-2009-4.3.3-1 (SICA): Comparative population genetic studies on multifactorial diseases.	Only up to one project can be selected. SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from Russia.
4.3.3.	HEALTH-2009-4.3.3-2: Mechanisms of diabetic and weight-related co-morbidity in heart failure (SICA).	Only up to one project can be selected. SICA – Minimum number of participants: 2 from different Member States or associated countries and 2 from Russia.

In line with the objectives of each topic, additional eligibility criteria may be indicated in the work programme

Evaluation procedure: The basic principles of the Evaluation criteria for proposals are described in Annex 2 of the work programme. However, for this call, the priority order for proposals with the same score will be determined in the manner described under 'Proposal ranking' (see below).

For all proposals submitted to this call the evaluation shall follow a single stage procedure. The proposers are requested to follow the instructions set out in the guide for applicants and in the proposal part B template available through the EPSS, including page number limitations and a minimum font size of 11. The Commission will instruct the experts to disregard any pages in excess of these limits. The proposals will be evaluated by external experts on the basis of three evaluation criteria. The individual evaluation will be carried out remotely and the consensus meetings of evaluators will be held in Brussels.

Evaluation criteria and thresholds: For this call the following criteria and thresholds are applied. For each criterion marks from 0 to 5 will be given, with the possibility of half point scores. For proposals failing to achieve a threshold for a criterion, the evaluation of the proposal will be stopped at the first criterion failing a threshold. Therefore for such proposals the ESR (evaluation summary report) will not contain marks and comments for the remaining criteria. Successful proposals must pass the following minimum thresholds:

Table 5: Thresholds for evaluation criteria

Criterion	Minimum threshold
S/T quality	3/5
Implementation	3/5
Impact	3/5
Overall threshold	10/15

In line with the objectives of each topic, additional evaluation criteria may be indicated in the work programme.

Proposal ranking: The series of priority lists will be prepared by the panels of external experts, per indicative sub-budget line as set out in this call fiche. The aspects taken into account for establishing a priority order for ranking of proposals are as follows:

- First by overall score;
- Second, proposals with the same overall score will be ranked based on the score for the Science and Technology (S/T) quality criterion;
- To avoid prioritising any proposals of similar content to those proposals with higher scores already on the list
- Then also to be taken into account: coverage of the work programme (the overall balance of proposals to be funded), provided proposals of sufficient quality have been submitted, and any strategic objectives and/or community policies specified in the work programme.

There will be differing numbers of proposals short-listed according to the funding scheme and topic. However, there may be topics for which no proposals are of sufficient quality to be selected for funding, as there will be competition within topics and between topics on the basis of the quality of the proposals.

- For Large-scale Integrating Projects, Networks of Excellence, Coordination and Support Actions, **up to one proposal** can be funded per topic, unless otherwise stated in the topic description in the topic description in table 4 (particular requirements for specific topics).
- For small and medium-scale Focused Research Projects, **one or more proposals** can be funded per topic, unless otherwise stated in the table.

The Commission ranked lists of proposals to be retained for negotiation will be based on the priority list established by the panel of external experts taking into account the budget available for each budget line (as indicated in this call for proposals). For each budget line, a number of proposals below the indicative budget cut-off line on the Commission ranked list may be kept on a reserve list to allow for eventualities such as the failure of negotiations on grant agreements, the withdrawal of proposals, budget savings agreed during negotiation, or the availability of additional budget from other sources.

Indicative evaluation and contractual timetable: The first stage evaluation should be finalised in February/March 2009. Overall evaluation results are estimated to be available within 4 months after the closure date for the call. It is expected that contract negotiations for short-listed proposals would begin in May/June 2009.

Consortium agreements: Participants in large-scale integrating projects are required to conclude a consortium agreement.

The forms of grants and maximum reimbursement rates which will be offered are specified in Annex 3 to the Cooperation work programme.